Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Apr;88(1):143–148. doi: 10.1111/j.1365-2249.1992.tb03054.x

Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.

L H Caldera 1, M Leon-Ponte 1, G Acquatella 1, N E Bianco 1, I Blanca 1
PMCID: PMC1554352  PMID: 1373350

Abstract

Natural killer (NK) cytotoxic activity was simultaneously investigated in bone marrow mononuclear cells (BMMC) and peripheral blood lymphocytes (PBL) from nine Hodgkin's disease (HD) and 15 non-Hodgkin lymphoma (NHL) untreated patients. Twenty-five PBL samples and seven bone marrow specimens from healthy individuals were also included as control group (C). NK cell activity was evaluated in basal condition and post-stimulation with human recombinant IL-2 (rIL-2). Data were expressed in K values (number of BMMC or PBL needed to lyse 50% of the target cells). In basal condition, both HD and NHL patients showed a NK cell activity comparable to the C group, both in BMMC (HD, K = 2.48 +/- 1.3; NHL, K = 3.8 +/- 2.0; C, K = 3.2 +/- 0.7) and PBL (HD, K = 2.0 +/- 1.0; NHL, K = 2.3 +/- 1.0; C, K = 2.2 +/- 0.2). Stimulation with rIL-2 induced a significant and comparable enhancement of the NK activity in PBL from HD, NHL and C while the response to rIL-2 of the BMMC in most of the HD and NHL patients was significantly greater than the C group. Responder cells were characterized by negative selection with specific MoAb plus complement as a CD3-, CD16+, CD56+ cytotoxic cell and further confirmed by flow cytometry. We postulate that IL-2 activation of bone marrow NK cell precursors, in addition to enhancing the activity of circulating NK, may be of value for the therapeutic rationale of IL-2 in patients with lymphoma.

Full text

PDF
143

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blanca I., Herberman R. B., Ortaldo J. R. Human natural killer cytotoxic factor. Studies on its production, specificity, and mechanism of interaction with target cells. Nat Immun Cell Growth Regul. 1985;4(1):48–59. [PubMed] [Google Scholar]
  2. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  3. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  4. Domzig W., Stadler B. M., Herberman R. B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol. 1983 Apr;130(4):1970–1973. [PubMed] [Google Scholar]
  5. Engleman E. G., Benike C. J., Hoppe R. T., Kaplan H. S., Berberich F. R. Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect. J Clin Invest. 1980 Jul;66(1):149–158. doi: 10.1172/JCI109828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Estevez M. E., Sen L., Bachmann A. E., Pavlovsky A. Defective function of peripheral blood monocytes in patients with Hodgkin's and non-Hodgkin's lymphomas. Cancer. 1980 Jul 15;46(2):299–302. doi: 10.1002/1097-0142(19800715)46:2<299::aid-cncr2820460214>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  7. Feo Figarella E., Morillo F., Blanca I., Bianco N. E. Failure of cell-mediated effector mechanisms in lung cancer. J Natl Cancer Inst. 1984 Jul;73(1):1–6. [PubMed] [Google Scholar]
  8. Frydecka I. Natural killer cell activity during the course of disease in patients with Hodgkin's disease. Cancer. 1985 Dec 15;56(12):2799–2803. doi: 10.1002/1097-0142(19851215)56:12<2799::aid-cncr2820561215>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  9. Gilewski T. A., Richards J. M. Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol. 1990 Feb;17(1):74–87. [PubMed] [Google Scholar]
  10. Grönvik K. O., Andersson J. The role of T cell growth stimulating factors in T cell triggering. Immunol Rev. 1980;51:35–59. doi: 10.1111/j.1600-065x.1980.tb00316.x. [DOI] [PubMed] [Google Scholar]
  11. Gupta S., Fernandes G. Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease. Clin Exp Immunol. 1981 Jul;45(1):205–214. [PMC free article] [PubMed] [Google Scholar]
  12. Haller O., Kiessling R., Orn A., Wigzell H. Generation of natural killer cells: an autonomous function of the bone marrow. J Exp Med. 1977 May 1;145(5):1411–1416. doi: 10.1084/jem.145.5.1411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Herberman R. B., Ortaldo J. R. Natural killer cells: their roles in defenses against disease. Science. 1981 Oct 2;214(4516):24–30. doi: 10.1126/science.7025208. [DOI] [PubMed] [Google Scholar]
  14. Jhaver K. G., Advani S. H., Nadkarni J. J. Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients. Immunol Lett. 1990 Jun;24(3):217–223. doi: 10.1016/0165-2478(90)90051-q. [DOI] [PubMed] [Google Scholar]
  15. Kalland T. Generation of natural killer cells from bone marrow precursors in vitro. Immunology. 1986 Apr;57(4):493–498. [PMC free article] [PubMed] [Google Scholar]
  16. Kiessling R., Wigzell H. An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev. 1979;44:165–208. doi: 10.1111/j.1600-065x.1979.tb00270.x. [DOI] [PubMed] [Google Scholar]
  17. Koo G. C., Peppard J. R., Mark W. H. Natural killer cells generated from bone marrow culture. J Immunol. 1984 May;132(5):2300–2304. [PubMed] [Google Scholar]
  18. Lotzová E., Savary C. A. Generation of NK cell activity from human bone marrow. J Immunol. 1987 Jul 1;139(1):279–284. [PubMed] [Google Scholar]
  19. Lozzio C. B., Lozzio B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975 Mar;45(3):321–334. [PubMed] [Google Scholar]
  20. Miller S. C. Production and renewal of murine natural killer cells in the spleen and bone marrow. J Immunol. 1982 Nov;129(5):2282–2286. [PubMed] [Google Scholar]
  21. Ortaldo J. R., Blanca I., Herberman R. B. Studies of human natural killer cytotoxic factor (NKCF): characterization and analysis of its mode of action. Adv Exp Med Biol. 1985;184:203–220. doi: 10.1007/978-1-4684-8326-0_14. [DOI] [PubMed] [Google Scholar]
  22. Oshimi K., Oshimi Y., Yamada O., Mizoguchi H. Lysis of lymphoma cells by autologous and allogeneic natural killer cells. Blood. 1985 Mar;65(3):638–643. [PubMed] [Google Scholar]
  23. Perussia B., Trinchieri G. Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells. J Immunol. 1984 Mar;132(3):1410–1415. [PubMed] [Google Scholar]
  24. Rodriguez M. A., Blanca I., Baroja M. L., Arama S., Leon-Ponte M., Abadi I., Bianco N. E. Helper activity by human large granular lymphocytes in in vitro immunoglobulin synthesis. J Clin Immunol. 1987 Sep;7(5):356–364. doi: 10.1007/BF00917013. [DOI] [PubMed] [Google Scholar]
  25. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  26. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  27. Schulof R. S., Bockman R. S., Garofalo J. A., Cirrincione C., Cunningham-Rundles S., Fernandes G., Day N. K., Pinsky C. M., Incefy G. S., Thaler H. T. Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease. Cancer. 1981 Aug 15;48(4):964–973. doi: 10.1002/1097-0142(19810815)48:4<964::aid-cncr2820480419>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  28. Suzuki R., Handa K., Itoh K., Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. J Immunol. 1983 Feb;130(2):981–987. [PubMed] [Google Scholar]
  29. Timonen T., Ortaldo J. R., Herberman R. B. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981 Mar 1;153(3):569–582. doi: 10.1084/jem.153.3.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Timonen T., Ortaldo J. R., Stadler B. M., Bonnard G. D., Sharrow S. O., Herberman R. B. Cultures of purified human natural killer cells: growth in the presence of interleukin 2. Cell Immunol. 1982 Sep 1;72(1):178–185. doi: 10.1016/0008-8749(82)90295-7. [DOI] [PubMed] [Google Scholar]
  31. Trinchieri G., De Marchi M., Mayr W., Savi M., Ceppellini R. Lymphocyte antibody lymphocytolytic interaction (LALI) with special emphasis on HL-A. Transplant Proc. 1973 Dec;5(4):1631–1649. [PubMed] [Google Scholar]
  32. Tursz T., Dokhelar M. C., Lipinski M., Amiel J. L. Low natural killer cell activity in patients with malignant lymphoma. Cancer. 1982 Dec 1;50(11):2333–2335. doi: 10.1002/1097-0142(19821201)50:11<2333::aid-cncr2820501119>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  33. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  34. Zamkoff K. W., Dock N. L., Kurec A. S., Davey F. R. Diminished autologous mixed lymphocyte reaction in patients with Hodgkin disease: evidence for non-T cell dysfunction. Am J Hematol. 1982 Jun;12(4):327–335. doi: 10.1002/ajh.2830120404. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES